- Neurospa currently operates six interventional psychiatry
clinics on Florida's Gulf
Coast
- HOPE to acquire majority interest in Neurospa for a
combination of cash and equity
- Neurospa clinics deliver a full range of interventional
psychiatry services, including Ketamine, Spravato®
and Transcranial Magnetic Stimulation (TMS) to patients with
severe depression and related conditions
- Acquisition to be accretive to HOPE revenue projections for
2025
MIAMI, March 24,
2025 /PRNewswire/ -- HOPE Therapeutics, Inc.,
("HOPE," the "Company"), an interventional psychiatry network
wholly owned by NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq:NRXP),
today announced signing of a binding Letter of Intent to acquire a
majority interest in Neurospa TMS Holdings, LLC, LLC (Neurospa).
Neurospa operates six interventional psychiatry clinics on
Florida's Gulf Coast and will
constitute a key element of HOPE's Florida network going forward. Neurospa is
revenue generating and EBITDA positive.
Neurospa leverages state-of-the-art interventional psychiatry
procedures, including Ketamine Infusion Therapy, Transcranial
Magnetic Stimulation (TMS), and Spravato®, augmented by
traditional psychiatry and talk therapy to provide a full continuum
of care for people with depression, suicidality, PTSD, anxiety, and
related disorders. TMS is an FDA-approved procedure in which
focused electromagnetic treatment has been demonstrated to reduce
symptoms of depression. Ketamine and Spravato® are
similarly known to reduce symptoms of depression and both forms of
treatment are increasingly used in an additive manner.
Neurospa provides a physician-led, welcoming spa-like
environment that puts patient's needs and comfort first. Neurospa's
outstanding team of dedicated professionals are to become key
members of the HOPE team upon closing of the transaction.
"Neurospa was founded with the mission to provide TMS
therapy for patients in the Tampa
Bay area, and has grown to provide comprehensive,
cutting-edge care to patients in our six clinics in west central
Florida; the team has made great
progress achieving this exceptional level of care. We're eager to
accelerate that mission by joining the HOPE Network," said
Renier Gobea, Founder of
Neurospa.
"We are thrilled to welcome the Neurospa team to the HOPE
network and look forward to the contribution they will continue to
make to their patients and to the expansion of the HOPE network
statewide," said Jonathan Javitt, MD
MPH and Matthew Duffy, Co-CEOs of
HOPE Therapeutics.
The intended acquisition of Neurospa is subject to the
completion of financial audits, execution of definitive agreements,
and the satisfaction of standard closing conditions.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a
healthcare delivery company currently developing a best-in-class
network of interventional psychiatry clinics to offer
psychedelic medications, including ketamine and
Spravato®, combined with Transcranial Magnetic
Stimulation (TMS) and other lifesaving, neuroplastic therapies to
patients with suicidal depression and related disorders, together
with a digital therapeutic-enabled platform designed to augment and
preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain, and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx plans to file an NDA for Accelerated Approval for
NRX-101 in patients with bipolar depression and suicidality or
akathisia.
NRx recently announced initiation of filing a New Drug
Application for NRX-100 (IV ketamine) for the treatment of suicidal
depression, based on results of well-controlled clinical trials
conducted under the auspices of the US National Institutes of
Health and newly obtained data from French health authorities,
licensed under data sharing agreements. NRx was awarded Fast Track
Designation for development of ketamine (NRX-100) by the US FDA as
part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, among others,
statements regarding the satisfaction of closing conditions
necessary to consummate the acquisition of Kadima, Neurospa and
Dura, and obtaining financing necessary to consummate the
acquisitions. Forward-looking statements generally include
statements that are predictive in nature and depend upon or refer
to future events or conditions, and include words such as "may,"
"will," "should," "would," "expect," "plan," "believe," "intend,"
"look forward," and other similar expressions among others. These
statements relate to future events or to the Company's future
financial performance, and involve known and unknown risks,
uncertainties and other factors that may cause the Company's actual
results to be materially different from any future results, levels
of activity, performance or achievements expressed or implied by
these forward-looking statements. You should not place undue
reliance on forward-looking statements since they involve known and
unknown risks, uncertainties and other factors which are, in some
cases, beyond the Company's control and which could, and likely
will, materially affect actual results, levels of activity,
performance or achievements. Any forward-looking statement reflects
the Company's current views with respect to future events and is
subject to these and other risks, uncertainties and assumptions
relating to the Company's operations, results of operations, growth
strategy, liquidity, Hope Therapeutic's ability to consummate the
acquisitions of providers for its national network, the Company's
ability to raise adequate capital to fund such acquisitions, and
the Company's ability to spin-off Hope Therapeutics. More
detailed information about the Company and the risk factors that
may affect the realization of forward-looking statements is set
forth in the Company's most recent Annual Report on Form 10-K and
other filings with the Securities and Exchange Commission.
Investors and security holders are urged to read these documents
free of charge on the SEC's website at http://www.sec.gov.
Except as may be required by applicable law, The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, whether as a result of new information,
future events or otherwise.
For further information:
Matthew Duffy
Co-Chief Executive Officer, HOPE
Therapeutics, Inc.
Chief Business Officer, NRx Pharmaceuticals, Inc.
mduffy@nrxpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-signing-of-binding-letter-of-intent-with-neurospa-tms-holdings-llc-for-expansion-of-its-planned-international-network-of-interventional-psychiatry-clini-302408763.html
SOURCE NRx Pharmaceuticals, Inc.
